Aminah Alotaibi | Breast Cancer | Best Researcher Award

Published on by Oncology

Dr. Aminah Alotaibi | Breast Cancer | Best Researcher Award

Assistant Research Professor | King Abdulaziz city for science and technology | Saudi Arabia

Dr. Aminah Ghazi Alotaibi is a distinguished researcher affiliated with the King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia. With a Scopus h-index of 3, 4 indexed publications, and 58 citations, she has demonstrated consistent scholarly impact in the fields of hematology, stem cell biology, and molecular diagnostics. Her research primarily focuses on elucidating the phenotypic and molecular diversity of hematopoietic stem and progenitor cells (HSPCs) derived from cord blood and bone marrow, advancing the understanding of their biological significance and translational potential in clinical applications. Notably, her recent open-access article titled “Distinct Phenotypic and Molecular Characteristics of CD34− and CD34+ Hematopoietic Stem/Progenitor Cell Subsets in Cord Blood and Bone Marrow Samples: Implications for Clinical Applications” (2025, Diagnostics) highlights her expertise in cellular characterization and regenerative medicine, offering valuable insights for stem cell-based therapies and transplantation science. Dr. Alotaibi’s collaborative network spans 23 co-authors, reflecting her active engagement in multidisciplinary and international scientific research. Her work integrates clinical hematology, genomics, and translational biomedical research, bridging the gap between laboratory discoveries and patient-centered innovations. Through her contributions, she aims to enhance diagnostic precision, therapeutic efficacy, and personalized medical approaches in hematologic and immune-related disorders. Dr. Alotaibi’s scholarly endeavors not only strengthen Saudi Arabia’s presence in global biomedical research but also contribute to the broader scientific community’s understanding of stem cell biology and its clinical potential.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

1. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2021). Tumour necrosis factor-α (TNF-α) enhances dietary carcinogen-induced DNA damage in colorectal cancer epithelial cells through activation of JNK signaling pathway. Toxicology, 457, 152806. Cited by: 36

2. Al-Saleh, I., Elkhatib, R., Al-Rajoudi, T., Al-Qudaihi, G., Manogarannogaran, P., Alotaibi, A. G., & others. (2020). Cytotoxic and genotoxic effects of e-liquids and their potential associations with nicotine, menthol and phthalate esters. Chemosphere, 249, 126153. Cited by: 22

3. Alotaibi, A. G., Li, J. V., & Gooderham, N. J. (2023). Tumour necrosis factor-alpha (TNF-α)-induced metastatic phenotype in colorectal cancer epithelial cells: Mechanistic support for the role of microRNA-21. Cancers, 15(3), 627. Cited by: 21

4. Gaafar, A., Hamza, F. N., Yousif, R., Shinwari, Z., Alotaibi, A. G., Iqniebi, A., & others. (2025). Distinct phenotypic and molecular characteristics of CD34− and CD34+ hematopoietic stem/progenitor cell subsets in cord blood and bone marrow samples: Implications for clinical applications. Diagnostics, 15(4), 447. Cited by: 1

5. Alotaibi, A. G. (2023). Effect of the inflammatory mediator TNF-α on colorectal cancer epithelial cells development and metastasis, role of dietary carcinogens and miRNA [Doctoral dissertation, Imperial College London]. Imperial College Repository.

Dr. Aminah Ghazi Alotaibi’s research advances global understanding of inflammation-driven carcinogenesis and stem cell biology, bridging molecular insights with clinical translation. Her work contributes to precision oncology, regenerative medicine, and the development of safer therapeutic strategies, fostering innovation that benefits both scientific progress and human health worldwide.

Mirjana Popadić | Carcinoma | Best Researcher Award

Published on by Oncology

Dr. Mirjana Popadić | Carcinoma | Best Researcher Award

Dermatovenerologist-Oncologist | Medigroup | Serbia

Dr. Mirjana Popadić is a distinguished researcher and faculty member at the University of Belgrade, Serbia, with a strong academic and clinical focus on dermatology, particularly in the diagnostic and histopathological evaluation of skin lesions. Over the course of her career, she has contributed significantly to the advancement of dermatological science, with 15 published research documents and over 121 citations, reflecting her growing influence within the global dermatology research community. Her work bridges the gap between clinical practice and experimental dermatopathology, with a special emphasis on innovative diagnostic techniques such as vertical ex vivo dermoscopy, a promising approach for improving the accuracy and differentiation of cutaneous lesions. Dr. Popadić’s research output, characterized by methodological precision and translational value, underscores her commitment to enhancing diagnostic reliability and patient outcomes in dermatologic oncology and inflammatory skin diseases. With an h-index of 7, her studies have been cited and utilized by peers across multiple institutions, demonstrating her active engagement in international scholarly collaboration. She has co-authored with nine other researchers, reflecting her interdisciplinary approach and contribution to collective scientific advancement. As a representative of the University of Belgrade, Dr. Popadić’s work not only reinforces Serbia’s academic presence in global dermatological research but also provides essential insights into the development of evidence-based diagnostic methodologies. Her scholarly contributions, teaching involvement, and clinical expertise together form a robust academic profile dedicated to the pursuit of excellence in skin pathology research, medical education, and healthcare innovation.

Profiles: Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Popadić, M., Brasanac, D., Milošev, D., Ravić Nikolić, A., & Mitrović, S. (2024). Vertical ex vivo dermoscopy in assessment of malignant skin lesions. Biomedicines, 12(8), 1683.

2. Popadić, M. (2018). Dermatoscopy of multiple piloleiomyomas with disseminated and segmental distribution. Indian Journal of Dermatology, Venereology and Leprology.

3. Popadić, M. (2018). Cutaneous polyarteritis nodosa: Uncommon and rare form of cutaneous vasculitis. Serbian Journal of Dermatology and Venereology, 10(2), 65–70.

4. Popadić, M. (2017). The significance of blue color in dermatoscopy. Journal der Deutschen Dermatologischen Gesellschaft (JDDG).

5. Popadić, M. (2016). Dermatoscopy in diagnosing maculopapular cutaneous mastocytosis. Praxis Medica.

Dr. Mirjana Popadić’s research advances the precision and reliability of dermatological diagnostics through innovative dermoscopic and histopathological techniques. Her contributions enhance early detection of malignant and rare skin disorders, bridging clinical practice and research to improve patient outcomes and promote global standards in dermatologic oncology.

Omar Alqaisi | Skin Cancer | Best Researcher Award

Published on by Oncology

Mr. Omar Alqaisi | Skin Cancer | Best Researcher Award

Al-Zaytoonah University of Jordan | Jordan

Dr. Omar M. Alqaisi is a dedicated academic and researcher at Al-Zaytoonah University of Jordan whose scholarly contributions reflect a strong commitment to advancing healthcare through evidence-based nursing practice and oncology research. With 11 published documents, 46 citations, and an h-index of 3, his work demonstrates a consistent trajectory of academic growth and increasing impact in the fields of clinical nursing, psycho-oncology, and patient-centered care. His notable publication, “A Narrative Review of the Roles of Nursing in Addressing Sexual Dysfunction in Oncology Patients,” underscores his focus on addressing sensitive and underexplored areas of oncology, particularly the psychosocial and emotional well-being of cancer patients, while emphasizing the indispensable role of nurses in holistic recovery and improving quality of life. A hallmark of his career is his emphasis on interdisciplinary collaboration, evidenced by co-authorship with more than 100 researchers across multiple disciplines, reflecting his ability to foster teamwork and integrate diverse perspectives to address complex healthcare challenges. His research is characterized by analytical precision, ethical grounding, and a human-centered approach, aligning with global healthcare trends that prioritize compassion, inclusivity, and evidence-based interventions. Beyond individual studies, Dr. Alqaisi’s work contributes to the broader advancement of nursing education, clinical practice, and patient advocacy in oncology. His growing academic influence positions him as an emerging leader within regional and international research communities. With continued development in empirical methodologies, digital health innovations, and cross-cultural healthcare models, he is poised to expand his contributions to global nursing and oncology discourse. Dr. Alqaisi’s research not only advances academic understanding but also creates meaningful societal impact by emphasizing empathy, communication, and the integration of psychosocial care into clinical frameworks, exemplifying a new generation of scholars committed to bridging scientific innovation with humanistic healthcare practice.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

1. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, October 9). Immune checkpoint inhibitors in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Cancers, 17(19), 3272.

2. Alqaisi, O., Al-Ghabeesh, S., Tai, P., Wong, K., Joseph, K., & Yu, E. (2025, August 14). A narrative review of the roles of nursing in addressing sexual dysfunction in oncology patients. Current Oncology, 32(8), 457.

3. Tai, P., Alqaisi, O., Al-Ghabeesh, S., Sijarina, L., Yu, E., Thachuthara, A. J., Assouline, A., Souied, O., Hagel, K., & Joseph, K. (2025, July 25). Immunotherapy in Merkel cell carcinoma of the skin: A 2025 comprehensive review. Preprints, 202507.2063.v1.

4. Alqaisi, O., Subih, M., Joseph, K., Yu, E., & Tai, P. (2025, June). Oncology nurses’ attitudes, knowledge, and practices in providing sexuality care to cancer patients: A scoping review. Current Oncology, 32(6), 337.

5. Alqaisi, O. M., & Al-Ghabeesh, S. (2024, July 31). Quality of postoperative pain management in orthopedic patients and its impact on sleep quality and patient satisfaction: An integrative review. Cureus, 16(7), e65872.

Dr. Omar M. Alqaisi’s research advances the integration of compassionate, evidence-based nursing within oncology care, addressing both clinical and psychosocial patient needs. His work strengthens global healthcare practices by promoting interdisciplinary collaboration, enhancing patient quality of life, and shaping innovative models for holistic, human-centered medical care.

Melissa Christiaens | Cervical Cancer | Best Researcher Award

Published on by Oncology

Dr. Melissa Christiaens | Cervical Cancer | Best Researcher Award

Radiation-Oncology | University Hospitals Leuven | Belgium

Dr. Melissa Christiaens is a highly accomplished Radiation Oncologist recognized for her contributions to the advancement of radiotherapy and clinical oncology research. With extensive experience in oncological treatment, she has played a key role in integrating evidence-based radiotherapy techniques into modern cancer care. Her professional expertise spans across radiotherapy quality assurance, pediatric oncology, gynecologic cancers, and multidisciplinary tumor management. As an active member of several leading scientific organizations—including the European Society for Radiotherapy and Oncology, the Paediatric Radiation Oncology Society, the European Society of Gynaecological Oncology, the EuroEwing Consortium, and the Connective Tissue Oncology Society—she consistently collaborates in large-scale international research networks to improve patient outcomes and optimize therapeutic protocols. Her research interests focus on clinical trials in radiotherapy, immuno-oncology integration, and precision treatment strategies for rare and complex cancers. Dr. Christiaens has contributed to numerous high-impact peer-reviewed journals such as The Lancet, Radiotherapy and Oncology, BMC Cancer, and Gynecologic Oncology, where her publications have enhanced the scientific understanding of cancer treatment outcomes, safety, and innovation. Her research skills encompass clinical data interpretation, protocol development, treatment optimization, and evidence synthesis—supported by her commitment to maintaining the highest standards of clinical excellence. Throughout her career, she has demonstrated exceptional leadership in oncology research and education, promoting collaboration and innovation within the global cancer research community. Her achievements continue to inspire advancements in patient-centered cancer therapy and clinical radiobiology. Her enduring scientific legacy is reflected through 1,417 citations, 25 documents, and an h-index of 12, underscoring her influential role in advancing the frontiers of clinical radiotherapy, oncology innovation, and multidisciplinary cancer research.

Profiles: Google Scholar | Scopus | ResearchGate

Featured Publications

1. Pötter, R., Tanderup, K., Schmid, M. P., Jürgenliemk-Schulz, I., Haie-Meder, C., & Christiaens, M., et al. (2021). MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): A multicentre prospective cohort study. The Lancet Oncology, 22(4), 538–547. Cited by: 613

2. Zhang, H., Ahearn, T. U., Lecarpentier, J., Barnes, D., Beesley, J., Qi, G., Jiang, X., & Christiaens, M., et al. (2020). Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 52(6), 572–581. Cited by: 466

3. Lorusso, D., Xiang, Y., Hasegawa, K., Scambia, G., Leiva, M., Ramos-Elias, P., & Christiaens, M., et al. (2024). Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18). The Lancet, 404(10460), 1321–1332. 
Cited by: 323

4. Ajithkumar, T., Horan, G., Padovani, L., Thorp, N., Timmermann, B., Alapetite, C., & Christiaens, M., et al. (2018). SIOPE–Brain tumor group consensus guideline on craniospinal target volume delineation for high-precision radiotherapy. Radiotherapy and Oncology, 128(2), 192–197. Cited by: 113

5. De Ruysscher, D., Sharifi, H., Defraene, G., Kerns, S. L., & Christiaens, M., et al. (2013). Quantification of radiation-induced lung damage with CT scans: The possible benefit for radiogenomics. Acta Oncologica, 52(7), 1405–1410. Cited by: 74

Permal Deo | Prostate Cancer | Best Researcher Award

Published on by Oncology

Dr. Permal Deo | Prostate Cancer | Best Researcher Award

Senior Lecturer | Clinical and Health Sciences, University of South Australia | Australia

Dr. Permal Deo is a distinguished food scientist and academic leader renowned for his contributions to nutrition, food biochemistry, and public health research. He holds a PhD in Food Biochemistry from Queen’s University Belfast, UK, where his doctoral work investigated the effects of food-derived advanced glycation end-products (AGEs) on oxidative stress and receptor activity in human cell lines. Complementing this, he earned a Master of Applied Science and Postgraduate Diploma from The University of Queensland, Australia, and a Bachelor of Science from The University of the South Pacific, Fiji. With over two decades of academic, research, and industry experience, Dr. Deo’s expertise encompasses food microbiology, food processing, functional foods, and the molecular pathways linking type 2 diabetes and Alzheimer’s disease. His research emphasizes the bioactivity of natural plant compounds and nutraceuticals in combating oxidative stress and inflammation, as well as the antimicrobial and food safety applications of electrochemically activated solutions. An accomplished mentor and research leader, he has supervised numerous postgraduate students and attracted more than AUD 2.5 million in competitive funding from prestigious bodies including the Australian Research Council, Diabetes Australia, and Horticulture Innovation. His extensive collaborations with institutions such as CSIRO, Monash University, and the University of Adelaide have advanced understanding in genome stability, indigenous food systems, and sustainable nutrition technologies. Widely recognized for his scholarly impact and leadership, Dr. Deo has presented at global scientific conferences and published influential studies in leading journals. His enduring scientific legacy is reflected through 944 citations, 57 documents, and an h-index of 19, underscoring his influential role in advancing the frontiers of food biochemistry, nutritional science, and biomedical innovation.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Snelson, M., Tan, S. M., Clarke, R. E., De Pasquale, C., Thallas-Bonke, V., Deo, P., … & Coughlan, M. T. (2021). Processed foods drive intestinal barrier permeability and microvascular diseases. Science Advances, 7(14), eabe4841. Cited by: 148

2. Sim, D. P., Khazandi, M., Chan, W. Y., Deo, P., & Trott, D. J. (2019). Antimicrobial activity of thyme oil, oregano oil, thymol and carvacrol against sensitive and resistant microbial isolates from dogs with otitis externa. Veterinary Dermatology. Cited by: 106

3. Deo, P., Hewawasam, E., Karakoulakis, A., Claudie, D. J., Nelson, R., & Vemulpad, S. (2016). In vitro inhibitory activities of selected Australian medicinal plant extracts against protein glycation, angiotensin converting enzyme (ACE), and digestive enzymes linked to diabetes. BMC Complementary and Alternative Medicine, 16(1), 435. Cited by: 61

4. Bergamin, A., Mantzioris, E., Cross, G., Deo, P., Garg, S., & Hill, A. M. (2019). Nutraceuticals: Reviewing their role in chronic disease prevention and management. Pharmaceutical Medicine, 33(4), 291–309. Cited by: 60

5. Fenech, M., Knasmueller, S., Knudsen, L. E., Kirsch-Volders, M., Deo, P., … & Bonassi, S. (2021). “Micronuclei and Disease” special issue: Aims, scope, and synthesis of outcomes. Mutation Research/Reviews in Mutation Research, 788, 108384. Cited by: 54

6. Ferro, S., Amorico, T., & Deo, P. (2018). Role of food sanitising treatments in inducing the ‘viable but nonculturable’ state of microorganisms. Food Control, 91, 321–329. Cited by: 54

Ramon Mangues | Cancer | Best Research Article Award

Published on by Oncology

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301

Rami Ahmad | Cancer Therapy | Best Researcher Award

Published on by Oncology

Prof. Dr. Rami Ahmad | Cancer Therapy | Best Researcher Award

Senior Researcher | Czech Education and Scientific Network | Czech Republic

Prof. Dr. Rami Ahmad El-Nabulsi is a distinguished theoretical physicist and applied mathematician whose research bridges nonlinear quantum dynamics, fractal mechanics, plasma and solid-state physics, and advanced mathematical modeling. Holding a PhD in Particle and Mathematical Physics from AMU, along with postgraduate diplomas in Plasma Physics and degrees in Physics at both master’s and bachelor’s levels, he has built a prolific career combining theoretical rigor with computational innovation. He is currently affiliated with the Center of Excellence in Quantum Technology, Faculty of Engineering, and the Quantum-Atom Optics Laboratory at Chiang Mai University, Thailand, as well as with the University of South Bohemia and the Department of Optical Networks CESNET in the Czech Republic. Prof. El-Nabulsi’s research interests encompass geometrical and quantum dynamics, nonlinear systems, chaos and bifurcations, general relativity, quantum field theory, and the application of fractional and fractal calculus to complex systems in engineering, astrophysics, and materials science. His expertise extends to advanced computational modeling, partial differential equations, stochastic systems, and numerical simulations. He has received multiple international honors, including the Outstanding Scientist Research Award and the Lifetime Achievement Award. A reviewer for more than 250 scientific journals and an editorial board member in over 40 peer-reviewed publications, he has authored more than 390 research articles in high-impact international journals and is frequently invited as an honorary speaker at global conferences. Prof. El-Nabulsi’s academic dedication, multidisciplinary approach, and sustained research excellence continue to shape theoretical and applied physics worldwide. His scholarly impact is reflected in 4,873 citations, 277 documents, and an h-index of 35, underscoring his influential role in advancing modern fractal physics and nonlinear dynamical systems research.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

1. El-Nabulsi, R. A., & Anukool, W. (2025). Chaotic and fractal maps in higher-order derivative dynamical systems. Frontiers in Physics, 12, 1529644. Cited by: 8

2. El-Nabulsi, R. A., & Anukool, W. (2025). Qualitative financial modelling in fractal dimensions. Financial Innovation, 11, 42. Cited by: 6

3. El-Nabulsi, R. A. (2025). A fractional model to study soliton in presence of charged space debris at low-Earth orbital plasma region. IEEE Transactions on Plasma Science, 52(9), 4671–4693. Cited by: 4

4. El-Nabulsi, R. A., & Golmankhaneh, A. K. (2025). Propagation of waves in fractal spaces. Waves in Random and Complex Media. Cited by: 4

5. El-Nabulsi, R. A., & Anukool, W. (2025). Vlasov equation, waves and dispersion relations in fractal dimensions: Landau damping and the toroidal ion temperature gradient instability problem. Waves in Random and Complex Media. Cited by: 14

6. El-Nabulsi, R. A. (2024). Transition from circular to spiral waves and from Mexican hat to upside-down Mexican hat-solutions: The cases of local and nonlocal λ–ω reaction–diffusion–convection fractal systems with variable coefficients. Chaos, Solitons & Fractals, 189, 115737. Cited by: 3

7. El-Nabulsi, R. A. (2024). Modelling nematic liquid crystal in fractal dimensions. Medicine in Novel Technology and Devices, 24, 100334. Cited by: 7

Dr. Jyoti Srivastava | Targeted Cancer Therapy | Best Researcher Award

Published on by Oncology

Dr. Jyoti Srivastava | Targeted Cancer Therapy | Best Researcher Award

Senior Research Scientist at Moffitt Cancer Center, United States

Dr. Jyoti Srivastava is a leading figure in Targeted Cancer Therapy, with extensive expertise in developing innovative approaches to cancer treatment. Her work in Targeted Cancer Therapy spans multiple cancer types, emphasizing molecular targets and mechanisms of resistance. By integrating Targeted Cancer Therapy strategies with tumor biology research, she has advanced personalized medicine approaches. Targeted Cancer Therapy under her leadership incorporates novel biomarkers, translational research, and immune-oncology concepts. Her contributions in Targeted Cancer Therapy include pioneering nitrosylation inhibition strategies, improving MEK inhibitor sensitivity, and designing effective molecular interventions. With a focus on Targeted Cancer Therapy for melanoma, liver cancer, and other malignancies, Dr. Srivastava’s vision is shaping the future of precision oncology through continuous Targeted Cancer Therapy innovation.

Professional Profile

ORCID Profile | Google Scholar Profile 

Education 

Dr. Jyoti Srivastava’s educational background is deeply rooted in molecular biology and biotechnology, forming a strong foundation for her Targeted Cancer Therapy expertise. She has applied her academic training to explore the complexities of tumor microenvironments, translating this knowledge into advanced Targeted Cancer Therapy approaches. Her studies in biological sciences have enabled her to understand the genetic, molecular, and biochemical pathways critical for effective Targeted Cancer Therapy. Dr. Srivastava’s education emphasized research excellence, laboratory skills, and data analysis, all vital for Targeted Cancer Therapy development. The integration of theoretical knowledge and practical applications has allowed her to innovate in Targeted Cancer Therapy strategies. By bridging fundamental science with applied oncology, she continues to transform her educational insights into groundbreaking Targeted Cancer Therapy solutions.

Experience 

Dr. Jyoti Srivastava’s professional experience reflects a profound dedication to Targeted Cancer Therapy, spanning leadership roles in academia, pharmaceuticals, and research institutions. She has led multidisciplinary teams in Targeted Cancer Therapy projects addressing melanoma, hepatocellular carcinoma, and other cancers. Her expertise in Targeted Cancer Therapy includes molecular target identification, drug resistance mechanisms, and immune modulation. At major cancer centers and biotech companies, she has advanced Targeted Cancer Therapy pipelines from concept to preclinical validation. Her roles demanded integration of Targeted Cancer Therapy with molecular pharmacology, immunology, and translational science. These experiences in Targeted Cancer Therapy have established her as a trusted leader in the field, capable of delivering high-impact solutions for patients through innovative Targeted Cancer Therapy strategies.

Research Interest 

Dr. Jyoti Srivastava’s research interests center on Targeted Cancer Therapy innovations that address resistance and improve patient outcomes. She investigates molecular pathways relevant to Targeted Cancer Therapy, such as nitrosylation, MEK/ERK signaling, and tumor immune evasion. Her Targeted Cancer Therapy research extends to novel biomarkers, therapeutic combinations, and personalized treatment approaches. By leveraging biochemical, genomic, and proteomic tools, she explores how to optimize Targeted Cancer Therapy in challenging cancer subtypes. She is particularly interested in applying Targeted Cancer Therapy to melanoma and liver cancers, aiming to enhance efficacy and minimize toxicity. Her commitment to advancing Targeted Cancer Therapy drives her to continually explore new targets, mechanisms, and delivery systems to maximize therapeutic impact.

Award and Honor

Dr. Jyoti Srivastava has earned numerous awards and honors recognizing her outstanding contributions to Targeted Cancer Therapy research. These accolades celebrate her pioneering work in Targeted Cancer Therapy, particularly her breakthroughs in melanoma and hepatocellular carcinoma treatment. She has been acknowledged by prestigious scientific societies for her Targeted Cancer Therapy innovations, editorial leadership, and impactful publications. Her awards reflect excellence in Targeted Cancer Therapy across research, mentorship, and scientific communication. Dr. Srivastava’s recognition reinforces her position as a leading authority in Targeted Cancer Therapy, inspiring peers and students alike. Each award symbolizes a milestone in her journey to refine Targeted Cancer Therapy strategies and develop patient-focused solutions that redefine modern cancer care.

Research Skill

Dr. Jyoti Srivastava possesses a wide range of research skills essential for advancing Targeted Cancer Therapy. Her technical expertise includes molecular biology, cell signaling, proteomics, and translational oncology, all applied within Targeted Cancer Therapy frameworks. She excels in designing experiments that dissect cancer pathways relevant to Targeted Cancer Therapy and in analyzing complex datasets for clinical application. Her proficiency in developing targeted agents, validating biomarkers, and integrating omics data strengthens her Targeted Cancer Therapy initiatives. She is skilled in team leadership, grant writing, and multidisciplinary collaboration, ensuring that Targeted Cancer Therapy projects are both scientifically robust and clinically relevant. These research skills empower her to translate fundamental discoveries into impactful Targeted Cancer Therapy solutions.

Publication Top Notes 

Title: Increased RNA‐induced silencing complex (RISC) activity contributes to hepatocellular carcinoma
Authors: BK Yoo, PK Santhekadur, R Gredler, D Chen, L Emdad, S Bhutia, ...
Journal: Hepatology

Title: Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves …
Authors: PK Santhekadur, SK Das, R Gredler, D Chen, J Srivastava, C Robertson, ...
Journal: Journal of Biological Chemistry

Title: AEG-1/MTDH/Lyric: Clinical Significance
Authors: D Sarkar, PB Fisher
Journal: Advances in Cancer Research

Title: Astrocyte elevated gene-1 promotes hepatocarcinogenesis: novel insights from a mouse model
Authors: J Srivastava, A Siddiq, L Emdad, PK Santhekadur, D Chen, R Gredler, ...
Journal: Hepatology

Title: Staphylococcal nuclease domain containing-1 (SND1) promotes migration and invasion via angiotensin II type 1 receptor (AT1R) and TGFβ signaling
Authors: PK Santhekadur, M Akiel, L Emdad, R Gredler, J Srivastava, ...
Journal: FEBS Open Bio

Title: Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis
Authors: N Jariwala, D Rajasekaran, J Srivastava, R Gredler, MA Akiel, ...
Journal: International Journal of Oncology

Title: AEG-1/MTDH/LYRIC, the beginning: initial cloning, structure, expression profile, and regulation of expression
Authors: SG Lee, DC Kang, R DeSalle, D Sarkar, PB Fisher
Journal: Advances in Cancer Research

Title: Genetic deletion of AEG-1 prevents hepatocarcinogenesis
Authors: CL Robertson, J Srivastava, A Siddiq, R Gredler, L Emdad, ...
Journal: Cancer Research

Title: Combination of Nanoparticle-Delivered siRNA for Astrocyte Elevated Gene-1 (AEG-1) and All-trans Retinoic Acid (ATRA): An Effective Therapeutic Strategy for …
Authors: D Rajasekaran, J Srivastava, K Ebeid, R Gredler, M Akiel, N Jariwala, ...
Journal: Bioconjugate Chemistry

Title: AEG-1 regulates retinoid X receptor and inhibits retinoid signaling
Authors: J Srivastava, CL Robertson, D Rajasekaran, R Gredler, A Siddiq, ...
Journal: Cancer Research

Conclusion

Dr. Jyoti Srivastava’s career exemplifies excellence in Targeted Cancer Therapy, blending rigorous science with innovative clinical vision. Her journey in Targeted Cancer Therapy reflects dedication to improving patient outcomes through targeted, personalized approaches. She has consistently advanced the frontiers of Targeted Cancer Therapy by identifying novel targets, overcoming resistance, and integrating multidisciplinary methods. Through her research, leadership, and publications, she continues to shape the field of Targeted Cancer Therapy, inspiring collaboration and innovation. Her commitment to translating laboratory discoveries into patient-centered solutions ensures that Targeted Cancer Therapy remains at the forefront of cancer treatment strategies. Dr. Srivastava’s legacy will be defined by her transformative contributions to Targeted Cancer Therapy.

Shijia Lu | Medicine | Best Researcher Award

Published on by Oncology

Mr. Shijia Lu | Medicine | Best Researcher Award

Sanquan College of Xinxiang Medical University | China

AUTHOR PROFILE

ORCID ID

🏥MR. SHIJIA LU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Mr. Shijia Lu embarked on his academic journey with a Bachelor’s degree in Biotechnology from Sanquan College of Xinxiang Medical University. Demonstrating early interest in tumor-targeted therapy, he quickly advanced into translational research and academic publishing. His undergraduate years were marked by robust interdisciplinary learning, laying the foundation for integrating bioinformatics, network pharmacology, and molecular simulations in cancer research.

🩺PROFESSIONAL ENDEAVORS

Currently serving as the Associate Editor of Guide to Biomedical Research Tools, Mr. Lu also holds student membership in the Chinese Society for Biotechnology. His roles extend beyond editorial to include project leadership, drug discovery, and computational biology. He has successfully led and contributed to university-level and provincial scientific projects, focusing on innovative strategies to combat cancer resistance.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON MEDICINE

Mr. Lu’s research is centered on tumor-targeted therapies, especially those overcoming PCNA-mediated resistance. Notable among his contributions:

  • Invented the “Structural Coupling – Functional Synergy” strategy, bridging natural product EGCG and synthetic inhibitors for synergistic effects.

  • Designed AL-1/AL-3, novel dual-ligand inhibitors tackling L47V mutation resistance in cancer cells.

  • Engaged in multi-omics-driven screening for anti-cancer components in natural sources such as pomegranate peel.
    His integrative research style blends wet-lab validation with computational simulations (AutoDock Vina, Cytoscape, ESM-Fold), setting a new paradigm in anti-cancer drug design.

🌍IMPACT AND INFLUENCE

Lu’s research has received national-level recognition, influencing the development of next-generation PCNA inhibitors. His PCNA-targeted strategy, featured in In Silico Research in Biomedicine, provides a blueprint for multi-target drug designs. Through editorial and competition platforms, he has advocated bioinformatics integration in biomedical research, inspiring peer groups and junior researchers in China’s academic circuits.

🏆 ACCOLADES AND RECOGNITION

Awards:
🥈 Second Prize, National College Students’ Innovation and Entrepreneurship Competition (Medical Health Category)
🏅 Three national-level research competition awards
🌍 Two provincial-level foreign language translation awards

🏆LEGACY AND FUTURE CONTRIBUTIONS

Mr. Lu’s pioneering research in drug resistance mechanisms, particularly in PCNA-targeted therapy, promises long-term value to precision oncology. His interdisciplinary approach—linking structural biology, network pharmacology, and bioinformatics—will likely influence future drug discovery pipelines, especially for hard-to-treat tumors. He is poised to emerge as a thought leader in the next generation of biomedical researchers.

🧬CONCLUSION

With a dynamic blend of technical mastery, scientific curiosity, and a vision for impact, Mr. Shijia Lu is a rising biomedical innovator. His work addresses one of the greatest challenges in medicine today—anti-cancer drug resistance—while his leadership in academia and publishing continues to foster new frontiers in biotechnology and translational research.

📊🔬NOTABLE PUBLICATION:

Design and anti-drug resistance research of novel PCNA-targeted inhibitors based on network pharmacology and molecular docking

Authors: Shijia Lu; YiRan Zhen; Jinwen Sima; Jinle Wang; Qihao Zhu; Miaoyan Han; Mengdan Sang; Xuejiao Li; Bing Zhang; Zihan Wang; et al.

Journal: In Silico Research in Biomedicine

Year: 2025

Rui Liu | Tumor Radiobiology | Best Researcher Award

Published on by Oncology

Dr. Rui Liu | Tumor Radiobiology | Best Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

SCOPUS ID

GOOGLE SCHOLAR

🏥DR. RUI LIU: ACADEMIC AND PROFESSIONAL PROFILE

🎓EARLY ACADEMIC PURSUITS

Dr. Rui Liu began her academic journey with a strong foundation in biomedical sciences, eventually earning a Ph.D. from a prestigious institution renowned for excellence in public health and molecular oncology. Her early research experiences centered on cellular biology and radiation mechanisms, which laid the groundwork for her specialization in tumor radiobiology and DNA damage repair (DDR).

🩺PROFESSIONAL ENDEAVORS

Currently serving as a Lecturer at the School of Public Health, Wenzhou Medical University, Dr. Liu has dedicated herself to cutting-edge cancer research. With over five years of hands-on laboratory experience, she has developed deep expertise in molecular biology, gene editing (CRISPR-Cas9), animal modeling, bioinformatics, and cellular imaging technologies. Her academic career reflects a balance between rigorous research and impactful teaching, mentoring the next generation of oncology researchers.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR RADIOBIOLOGY

Dr. Liu’s core research explores the molecular intricacies of radiotherapy resistance, with a focus on DNA damage repair pathways and ferroptosis in tumor cells. She has pioneered studies that unravel how long non-coding RNAs (lncRNAs) like MALAT1 influence cancer cell radiosensitivity, potentially leading to enhanced radiotherapy strategies. Her work contributes valuable insights into overcoming therapeutic resistance in breast cancer and other solid tumors.

🌍IMPACT AND INFLUENCE

Dr. Liu’s research has significantly advanced understanding in her field, evidenced by 445+ citations, an H-index of 12, and impactful publications in SCI-indexed journals. She is an active voice in the scientific community, engaging in collaborative research with Jilin University and contributing to national and provincial projects. Her affiliations with professional societies amplify her influence in radiological toxicology and environmental biophysics.

🏆 ACCOLADES AND RECOGNITION

Notable Awards:

  • 🎓 National Scholarship for Doctoral Excellence

  • 🌟 Recognition as a promising young investigator in radiobiology

🏆LEGACY AND FUTURE CONTRIBUTIONS

As an emerging leader in radiation oncology research, Dr. Liu aims to translate molecular findings into clinical applications that improve therapeutic outcomes. She mentors student researchers and continues to expand her interdisciplinary work on novel radiotherapy biomarkers, synthetic lethality, and non-coding RNA therapeutics. Her commitment ensures sustained contributions to precision oncology and translational cancer science.

🧬CONCLUSION

Dr. Rui Liu exemplifies the next generation of scientists transforming cancer treatment through molecular radiobiology. With a robust publication record, interdisciplinary collaborations, and active academic service, she is poised to leave a lasting impact on oncology research, education, and clinical innovation. Her ongoing efforts promise to redefine therapeutic strategies for radiation-resistant cancers.

📊🔬NOTABLE PUBLICATION:

Title: Metal ions overloading and cell death
Authors: Y. Lai, F. Gao, R. Ge, R. Liu, S. Ma, X. Liu
Journal: Cell Biology and Toxicology
Year: 2024

Title: Post‐translational modifications of protein in response to ionizing radiation
Authors: X. Liu, R. Liu, Y. Bai, H. Jiang, X. Fu, S. Ma
Journal: Cell Biochemistry and Function
Year: 2020

Title: The comparison of epidemiological characteristics between confirmed and clinically diagnosed cases with COVID-19 during the early epidemic in Wuhan, China
Authors: F. Shi, H. Wen, R. Liu, J. Bai, F. Wang, S. Mubarik, X. Liu, Y. Yu, Q. Hong, J. Cao, …
Journal: Global Health Research and Policy
Year: 2021

Title: Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population
Authors: R. Liu, L. Ning, X. Liu, H. Zhang, Y. Yu, S. Zhang, W. Rao, J. Shi, H. Sun, Q. Yu
Journal: Oncotarget
Year: 2017

Title: The challenges of precision radiotherapy technology to the traditional theory of radiobiology
Authors: S. Ma, Z. Liang, Q. Chen, R. Liu, Y. Guo, X. Liu
Journal: Chinese Journal of Radiological Medicine and Protection
Year: 2019

Title: Tumor-associated macrophages in radiotherapy: Mechanisms of polarization, immune regulation and therapeutic strategies
Authors: S. Ma, Z. Liang, X. Liu, R. Liu
Journal: Frontiers in Oncology
Year: 2023